QUANTITATIVE IMAGING FOR EVALUATION OF RESPONSES TO CANCER THERAPIES (U01)(PAR-08-225)(NCI)
The Cancer Imaging Program has announced the formation of the Quantitative Imaging Network. Currently six sites have been funded. The QIN funding opportunity expires on 9/8/2011. There are 3 future receipt dates: October 5, 2010, February 5, 2011 and June 5, 2011. A2 submissions may only be made November 5, 2010; A1 submissions may be made on November 5, March5, and July 5. If you are planning a new submission, it is suggested that you use the October 5, 2010 date, in order to have a chance to submit a revised application in July 2011. It is suggested that applicants send a brief (no more than 2 pages) outline of their planned project to Dr. Robert Nordstrom (email@example.com) so that he may determine its responsiveness to the program announcement.
CLARIFICATION OF APPLICATION PAGE LIMITS FOR PAR-09-157: IN VIVO CELLULAR AND MOLECULAR IMAGING CENTERS (ICMICS) (P50) (NOT-CA-10-033) (NCI)
Twelve page limits are required for the Research Component, Developmental Fund, and Career Development sections.
BIOENGINEERING RESEARCH PARTNERSHIPS (BRP)[R01] (PAR-10-234) (MULTIPLE ICS, INCLUDING NCI)
Application Receipt Date(s): Standard dates.
Participating Institutes and Centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic, applied, and translational multi-disciplinary research that addresses important biological, clinical or biomedical research problems. In the context of this program, a partnership is a multi-disciplinary research team, that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior.
2011 NIH DIRECTOR'S PIONEER AWARD PROGRAM (DP1) (RFA-RM-10-008)
Application Receipt Date(s): September 13, 2010
The NIH Director's Pioneer Award program complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's laboratory or elsewhere.
2011 NIH DIRECTOR'S NEW INNOVATOR AWARD PROGRAM (DP2) (RFA-RM-10-009)
Application Receipt Date(s): September 20, 2010
The NIH Director's New Innovator (DP2) Award program was created in 2007 to support a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The research proposed for a New Innovator Award may be in any scientific area relevant to the mission of NIH (biological, behavioral, clinical, social, physical, chemical, computational, engineering, and mathematical sciences) but need not be in a conventional biomedical or behavioral discipline. The focus is on innovation and potential impact. Investigators who were not selected for an award in prior years may submit applications this year as long as they retain their ESI (early stage investigator) eligibility; however, all applications must be submitted as "new" applications regardless of any previous submission to the program.
NIH COMMON FUND TRANSFORMATIVE RESEARCH PROJECTS PROGRAM (R01) (RFA-RM-10-010)
Letter of Intent Receipt Date: September 27, 2010
Application Receipt Date: October 27, 2010
Common Fund programs are designed to foster new ways of doing research, to fill fundamental knowledge gaps, and to encourage risk taking to solve complex problems. The overarching criterion for Common Fund programs is that they are expected to transform the way research is conducted across the spectrum of health sciences. The primary objective of the Common Fund Transformative Research Projects program is to foster the submission, review and support of groundbreaking, exceptionally innovative, high risk, original and/or unconventional research projects that have the potential to create new or challenge existing scientific paradigms. Applicants to this Funding Opportunity Announcement (FOA) must clearly articulate (1) the fundamental issue to be addressed and its overarching importance to the scientific enterprise, (2) how the studies will either establish new paradigms or challenge existing ones, or how the research will otherwise have a transformative impact, and (3) how the proposed rationale and/or approaches significantly differ from current state of the art.
NIH EXTRAMURAL LOAN REPAYMENT PROGRAMS (LRP) (NOT-OD-10-105)
Application Period: Annually from September 1 through November 15
Through this general Notice, the National Institutes of Health (NIH) announces the continued availability of educational loan repayment under the extramural Loan Repayment Programs (LRP). This Notice contains general eligibility criteria for all five LRPs. Specific program objectives and eligibility criteria are included in each of the following five specific LRP Notices:
CLINICAL STUDIES OF SAFETY AND EFFECTIVENESS OF ORPHAN PRODUCTS RESEARCH PROJECT GRANT (R01) (RFA-FD-11-001) (FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT)
Application Receipt Date(s): February 2, 2011; February 1, 2012 Resubmission Due Date(s): October 14, 2011 and October 15, 2012
The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy.
BARRETT'S ESOPHAGUS TRANSLATIONAL RESEARCH NETWORK (U54)( RFA-CA-10-014)
Letter of Intent Receipt Date: December 5, 2010
Application Receipt Date: January 5, 2011
This National Cancer Institute funding opportunity announcement (FOA) solicits applications for multi-institutional, transdisciplinary, Translational Research Centers to serve as the main components of the Barrett's Esophagus Translational Research Network (BETRNet). Translational Research Centers are designed to conduct innovative, high impact transdiciplinary research that will ultimately lead to development of validated diagnostic tools as well as improved patient management. Examples of research topics include development of dynamic and real-time in vivo imaging technologies. Examples of desirable outcomes include advancing the development of theories and conceptual models, biological markers, and treatments or interventions.
Information about a pre-application conference call will be available at https://dcb.nci.nih.gov/News/Pages/Barrett'sEsophagusRFA.aspx.
URL for Coordinating Center (RFA-CA-10-015): http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-10-015.html
ALZHEIMER'S DISEASE CORE CENTERS (P30) (RFA-AG-11-005)(NIA)
Letter of Intent Receipt Date: September 13, 2010
Application Receipt Date: October 13, 2010
The National Institute on Aging (NIA) invites applications from qualified institutions for support of Alzheimer's Disease Core Centers (ADCCs). These centers are designed to support and conduct research on Alzheimer's disease (AD), to serve as shared research resources that will facilitate research in AD and related disorders, distinguish them from the processes of normal brain aging and mild cognitive impairment (MCI), provide a platform for training, develop novel techniques and methodologies, and translate these research findings into better diagnostic, prevention and treatment strategies.
PRE-APPLICATION FOR A BIOMEDICAL TECHNOLOGY RESEARCH CENTER (X02)(PAR-10-224)(NCRR)
Application Due Date(s): December 14, 2010; May 11, 2011; December 13, 2011; May 11, 2012; December 13, 2012
This FOA issued by the National Center for Research Resources, National Institutes of Health encourages pre-applications for national Biomedical Technology Research Centers (BTRCs). These Centers conduct research and development on new technology and new/improved instruments driven by the needs of basic, translational, and clinical researchers. The BTRCs are charged to make their technologies available, to train members of the research community in the use of the technologies, and to disseminate both the technologies and the Center's experimental results broadly. A detailed description of the required components of a BTRC can be found in PAR-10-225. Pre-applications are the first step in order to submit a full BTRC application for a new Center.
Technical Assistance Videocast for RFA-RR-10-007: Clinical and Translational Science Coordinating Center (U54) (NOT-RR-10-012) (NCRR)
Date: Thursday, September 2, 2010
Time: 1:30 - 3:00 p.m., EDT
Send Questions to: firstname.lastname@example.org
URL for RFA-RR-10-007: http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-10-007.html
BIOMEDICAL TECHNOLOGY RESEARCH CENTER (P41)(PAR-10-225)(NCRR)
See PAR-10-224 above for Pre-Application, which new applicants are strongly urged to submit.
Application Submission Dates(s): Standard dates apply
This FOA issued by the National Center for Research Resources encourages grant applications for national Biomedical Technology Research Centers. These Centers conduct research and development on new technologies and new/improved instruments driven by the needs of basic, translational, and clinical researchers.
INSTRUMENT DEVELOPMENT FOR BIOMEDICAL APPLICATIONS (R21)(RFA-RR-10-009)(NCRR)
Application Receipt Date: October 08, 2010
The primary intent of this FOA is to stimulate the development of instrumentation for biomedical research that will support achievement of biomedical breakthroughs. Proposals primarily focused in the areas of biomedical imaging, sensors, biomaterials, tissue engineering and rehabilitation engineering will be considered nonresponsive and withdrawn without review.
NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING PROGRAM PROJECT (P01) APPLICATIONS (PAR-10-233)
Letter of Intent Receipt Date: 30 days prior to Application Receipt Date (to request more than $500K, contact program staff 6 weeks or more prior to Application Receipt Date).
Application Receipt Date: Standard P01 dates apply
This FOA, issued by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) encourages investigator-initiated Program Project Grant (P01) applications from institutions/organizations in the broad areas of biomedical imaging and bioengineering enabled by relevant areas of the physical sciences, engineering, computer sciences, information science, and the medical and life sciences.
Other Funding Agencies
Canadian Institutes of Health Research Banting Postdoctoral Fellowships
These are prestigious two-year fellowships, worth $70,000 per year, and open to both Canadian and international researchers who have recently completed a PhD, PhD-equivalent, or health professional degree. Seventy fellowships will be awarded each year through CIHR, NSERC and SSHRC. The program is unique in its emphasis on the synergy between applicants and research institutions.
Notice of Intent to Publish a Request for Applications for Tumor Microenvironment Network (TMEN) (NOT-CA-10-032)(NCI)
The intended FOA is designed to foster multi-institutional and transdisciplinary groups that are capable of addressing complex issues involving the tumor microenvironment. The main goal of TMEN is to generate novel information about the dynamic complexity of tumor-host interactions in different organ systems. The emphasis is on using human tissues, albeit supplemented by experimental models. Prospective applicant teams are encouraged to consider broad areas of expertise. In addition to cancer biology, desirable areas of expertise might include, for example, bioengineering, biological imaging, immunology, pathology clinical oncology and systems biology.
Notice of Intent to Publish a Request for Applications for Training in Neuroimaging: Integrating First Principles and Applications (T90) (NOT-DA-10-024)(NIDA)
The National Institute on Drug Abuse (NIDA), in collaboration with the other NIH Institutes and Centers comprising the NIH Blueprint for Neuroscience Research, intends to reissue a Request for Applications (RFA) soliciting applications that focus on Training in Neuroscience Imaging: Integrating First Principles and Applications (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-06-011.html). This RFA is expected to be published in the Fall of 2010.
Enhancing Peer Review: New NIH Policy on Post-Submission Application Materials (NOT-OD-10-115)
This Notice serves to announce that the new NIH policy on post-submission grant application materials (NOT-OD-10-070; NOT-OD-10-104) will be effective for applications submitted for the September 25, 2010, receipt date and thereafter. For the majority of applications submitted for the September 25, 2010,receipt date and thereafter, the only post-submission grant application materials that the NIH will accept are those resulting from unforeseen administrative issues. Exceptions are described in the notice.
CIP DCIDE PROGRAM MORPHS INTO NExT
The Cancer Imaging Program's DCIDE program for providing data to investigators for their IND filings is being absorbed by the NCI Experimental Therapeutics Program (NExT). Submissions are due quarterly, on the 15th of February, May, August and November.
GUEST AUTHOR OPPORTUNITIES IN THE NIH MICAD DATABASE
The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at email@example.com. Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.
2010 World Molecular Imaging Congress
September 8-11, 2010, International Conference Center, Kyoto, Japan
ISMRM Workshop on Improving Cancer Treatment with Advanced MR
September 19-22, 2010, Santa Cruz, CA
ACRIN Annual Meeting
September 29 - October 1, 2010, Ritz-Carlton Pentagon City, Arlington, VA
ISMRM Workshop on MR Safety: RF Heating of the Human in MRI
October 15-17, 2010, Stillwater, MN
International Conference on the Ultrasonic Measurement and Imaging of Tissue Elasticity
October 16-19, 2010, Cliff Lodge Snowbird Ski and Summer Resort, Snowbird, UT
2nd International Symposium on MR-guided Focused Ultrasound
October 17-20, 2010, Westfield Marriott Washington Dulles, Chantilly, VA
7th Annual Memphis BioImaging Symposium
November 4-5, 2010, Fogelman Executive Conference Center, University of Memphis. Tennessee
November 28 - December 3, 2010, McCormick Place, Chicago, IL
4th Workshop on Small Animal SPECT
Center for Gamma-Ray Imaging, University of Arizona, December 8-10, 2010, Tucson, AZ.
2010 International Chemical Conference of Pacific Basin Societies (Pacifichem)
Biomarkers: PET/SPECT Imaging(#105)
December 15-20, 2010, Honolulu, HI
RSNA Clinical Trials Methodology Workshop
January 15-21, 2011, Scottsdale, AZ
ISMRM Workshop on Ultra High Field Systems & Applications: 7T & Beyond: Progress, Pitfalls & Potential, Lake Louise, Alberta, Canada - 21-23 February 2011
19th ISMRM Scientific Annual Meeting & Exhibition
Montreal, Quebec, Canada - 7-13 May 2011
The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (firstname.lastname@example.org).
Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531Fax: 301 480 3507